RxDoctor Payments Data

Bhavika Gandhi, MD

Internal Medicine · Wichita Falls, TXNPI 1790148112

Payments from drug & device makers

$2,950in general payments, 2019–2025

Across 138 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$595
  • Travere Therapeutics, Inc.$366
  • Bayer$339
  • AstraZeneca$274
  • Daiichi Sankyo Inc.$138
  • Otsuka America Pharmaceutical, Inc.$128
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,86697%
  • Education$843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,950 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$248,517
Medicare patients
672
Services billed
3,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$70,415
JardianceEmpagliflozin19$20,312
KerendiaFinerenone20$16,418
LokelmaSodium Zirconium Cyclosilicate13$10,494
Potassium Citrate ErPotassium Citrate14$1,898
Losartan Potassium158$1,691
Tacrolimus22$1,596
Metolazone11$767
Potassium Chloride44$732
Furosemide95$663
Lisinopril104$629
Nifedipine ErNifedipine34$522
Amlodipine Besylate85$508
Hydralazine Hcl50$466
Torsemide19$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$274$80,909106 claims
Boehringer IngelheimJardiance$44$20,31219 claims
BayerKerendia$339$16,41820 claims
ANI Pharmaceuticals, Inc.Valsartan$39$32336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →